LEIDEN, Netherlands & CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) --
ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen program, following a comprehensive post-hoc analysis of the data from the Phase 2/3 Illuminate trial in people with CEP290-mediated Leber congenital amaurosis 10, or LCA10, a severe inherited retinal disease. The Company also announced the completion of an in-depth strategic review designed to extend the Company’s runway and deliver on its commitment to advance RNA therapies for diseases with high unmet need.
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.